Promising Developments in BioRestorative Therapies' Phase 2 Trial
BioRestorative Therapies, Inc. (NASDAQ: BRTX), a pioneer in regenerative medicine, is excited to share the latest findings from their ongoing Phase 2 clinical trial of BRTX-100 aimed at addressing chronic lumbar disc disease (cLDD). Recently, this data, focusing on preliminary results over 26, 52, and 104 weeks from the first 15 patients, was presented by Francisco Silva, the Vice President of Research and Development, at a significant international conference.
These preliminary findings are optimistic as they show no serious adverse events reported, along with a reassuring absence of dose-limiting toxicity across the assessed duration. This bodes well not only for patient safety but also for the overall potential of the treatment.
Trial Results Overview
The U.S. Food and Drug Administration (FDA) sets forth a goal for an improvement of over 30% in both the Oswestry Disability Index (ODI) and Visual Analog Scale (VAS). Early data is already showcasing trends indicative of positive outcomes, surpassing the 30% threshold in these key measures. Below is a summary of the percentage of subjects demonstrating greater than a 50% improvement in function (ODI) and pain reduction (VAS) at different intervals:
Performance Metrics
The following tables delineate the results over time:
- Week 2: 0.0% of subjects showed improvement.
- Week 12: 13.33% of subjects experienced improvement.
- Week 26: A significant increase to 46.15% achieving improvement.
- Week 52: 70.0% showcased improvement.
- Week 104: 66.66% of subjects reported improvement.
“We are encouraged that the positive data from our ongoing Phase 2 trial of BRTX-100 in cLDD continues to align with our primary safety goals and reflect positive preliminary efficacy,” stated Lance Alstodt, the Chief Executive Officer of BioRestorative.
Details on the BRTX-100 Trial
BRTX-100 is a cutting-edge therapeutic solution tailored for areas in the body that struggle with blood circulation. This leading candidate is undergoing scrutiny in a comprehensive Phase 2 study that includes up to 99 participants across 16 clinical sites in the United States. Individuals in the trial will be assigned randomly to receive either BRTX-100 or a placebo, ensuring a dual-system of reference for evaluating its efficacy.
Innovative Techniques and Focus Areas
This product leverages a patient’s own cultured mesenchymal stem cells derived from bone marrow, marking a pivotal shift towards personalized medicine. BRTX-100 is designed for outpatient procedures where physicians will inject this solution into patients' damaged discs. The application of this procedure targets those who have not found relief through conventional non-invasive methods, providing an alternative approach before surgical options are considered.
The Vision of BioRestorative Therapies
Beyond their promising work with BRTX-100, BioRestorative Therapies is dedicated to advancing therapeutic products using cell and tissue protocols. Their objectives encompass treatments for disc disease and metabolic disorders, enriched by a robust BioCosmeceutical platform.
Expanding Horizons in Regenerative Medicine
BioRestorative's program involves not just spinal conditions, but also addresses obesity and metabolic disorders. This includes the development of therapies that utilize stem cells derived from brown adipose tissue, which have shown potential in regulating metabolic functions and promoting caloric burning.
Additionally, their BioCosmeceutical division aims to produce skin care products with benefits addressing cosmetic concerns like fine lines, showcasing the versatility and cross-industry applicability of their solutions.
BioRestorative provides continuous updates on their advancements and invites anyone interested in their journey to visit their official communications for more insights.
Frequently Asked Questions
What is the Phase 2 trial for BRTX-100?
The Phase 2 trial assesses the safety and efficacy of BRTX-100, a therapeutic designed for chronic lumbar disc disease.
What results were recently presented?
Preliminary data showed no serious adverse events and significant positive trends in patient outcomes over 26, 52, and 104 weeks.
How does BRTX-100 work?
BRTX-100 is made from a patient's own mesenchymal stem cells to target areas with poor blood flow, injected into damaged discs to facilitate healing.
What is the goal of the FDA in this trial?
The FDA has set a requirement for at least a 30% improvement in both the Oswestry Disability Index and Visual Analog Scale.
Where can I find more information about BioRestorative Therapies?
Additional details can be found on BioRestorative’s official website and within their scientific publications section.
